

EMEA Kimtech[™] Prizm[™]/Prizm[™] Xtra Gloves – Cytotoxic Drug Permeation Testing – Jan 2020

Re: Cytotoxic Drug Permeation testing on Kimtech™ Prizm™/Prizm™ Xtra Gloves

Dear Valued Customer,

Thank you for your enquiry about our Kimtech[™] Prizm[™] and Prizm[™] Xtra Gloves and their use for protection against chemical splash hazards by cytotoxic drugs.

We must caution that the selection of the most appropriate glove for a specific task should be carried out by a trained safety professional following a full risk assessment. It is Kimberly-Clark Professional's intent to provide data which can enable trained professionals to make an informed choice.

This letter contains the results of chemical permeation testing of cytotoxic drugs, performed on the following gloves only:

- > Kimtech[™] Prizm[™] Gloves Multi-layered Neoprene/Nitrile Product Codes 99221 to 99225
- > Kimtech[™] Prizm[™] Xtra Gloves Multi-Layered Neoprene/Nitrile Product Codes 99251 to 99255

This testing took place earlier in 2020 prior to the product launch in December 2020. We have used the same accredited laboratory that have performed the same analysis for us in the past.

Standard test method used	ASTM D6978-05 (Standard practice for assessment of resistance of medical gloves to permeation by chemotherapy drugs)
Analytical method	UV/Vis Spectrometry
Testing temperature	35,0°C +- 2.0
Collection system	Closed loop
Number of specimens tested	3/test
Location sample from	Cuff area

Testing Conditions:



K-C Confidential. The information contained in this document is intended for the use of the addressee(s) only and may contain privileged, confidential, or proprietary information that should not be distributed publicly without Kimberly-Clark's written consent.

Kimberly-Clark PROFESSIONAL

KIMTECH[®]

EMEA Kimtech[™] Prizm[™]/Prizm[™] Xtra Gloves – Cytotoxic Drug Permeation Testing – Jan 2020

Results are summarized in the below table:

Kimtech[™] Prizm[™] Gloves

KIIIItetii Fiiziii Gioves		
Cytotoxic Drug	Concentration (mg/ml)	Breakthrough Time (mins)
Carmustine	3.3	47
ThioTEPA	10.0	38
Fentanyl		>240
Gastric Acid		>240
Fentanyl in Gastric Acid		>240
Cisplatin	1.0	>240
Cyclophosphamide	20.0	>240
Dacarbazine	10.0	>240
Doxorubicin HCl	2.0	>240
Etoposide	20.0	>240
Fluorouracil	50.0	>240
Ifosfamide	50.0	>240
Mitoxantrone	2.0	>240
Paclitaxel	6.0	>240
Vincristine Sulfate	1.0	>240
Cabazitaxel	60.0	>240
Capecitabine	26.0	>240
Eribulin Mesylate	0.5	>240
Floxuridine	100.0	>240
Lenvatinib	20.0	>240
Pemetrexed	25.0	>240
Sorafenib Tosylate	200.0	>240
Tamoxifen	2.0	>240
Vinblastine Sulfate	1.0	>240
Vinorelbine	10.0	>240

Tests were carried out by an independent laboratory, under laboratory test conditions. These tests may not adequately replicate any specific condition of use. As Kimberly-Clark Professional[™] has no detailed knowledge or control over the conditions of end use, this data must be considered advisory only and Kimberly-Clark Professional[™] must decline any liability.



K-C Confidential. The information contained in this document is intended for the use of the addressee(s) only and may contain privileged, confidential, or proprietary information that should not be distributed publicly without Kimberly-Clark's written consent.

Kimberly-Clark PROFESSIONAL

KIMTECH[®]

EMEA Kimtech[™] Prizm[™]/Prizm[™] Xtra Gloves – Cytotoxic Drug Permeation Testing – Jan 2020



Kimtech[™] Prizm[™] Xtra Gloves

Cytotoxic Drug	Concentration (mg/ml)	Breakthrough Time (mins)
Carmustine	3.3	37
ThioTEPA	10.0	30
Fentanyl		>240
Gastric Acid		>240
Fentanyl in Gastric Acid		>240
Cisplatin	1.0	>240
Cyclophosphamide	20.0	>240
Dacarbazine	10.0	>240
Doxorubicin HCl	2.0	>240
Etoposide	20.0	>240
Fluorouracil	50.0	>240
Ifosfamide	50.0	>240
Mitoxantrone	2.0	>240
Paclitaxel	6.0	>240
Vincristine Sulfate	1.0	>240
Cabazitaxel	60.0	>240
Capecitabine	26.0	>240
Eribulin Mesylate	0.5	>240
Floxuridine	100.0	>240
Lenvatinib	20.0	>240
Pemetrexed	25.0	>240
Sorafenib Tosylate	200.0	>240
Tamoxifen	2.0	>240
Vinblastine Sulfate	1.0	>240
Vinorelbine	10.0	>240

Tests were carried out by an independent laboratory, under laboratory test conditions. These tests may not adequately replicate any specific condition of use. As Kimberly-Clark Professional[™] has no detailed knowledge or control over the conditions of end use, this data must be considered advisory only and Kimberly-Clark Professional[™] must decline any liability.

We hope this information has been useful. If you require further assistance, please contact use at <u>Kimtech.support@kcc.com</u>.

Yours Sincerely,

Franck Bureth EMEA Scientific Category Leader Kimtech[™] | Kimberly-Clark Professional[™]

K-C Confidential. The information contained in this document is intended for the use of the addressee(s) only and may contain privileged, confidential, or proprietary information that should not be distributed publicly without Kimberly-Clark's written consent.

Kimberly-Clark